Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Fisher

Pain Medicine Las Vegas, NV Medical Doctor

NPI 1396944740 CMS profile 830124

7140 Smoke Ranch Rd Ste 150, Las Vegas, NV 89128

Open in the dashboard

General payments

$13,060

681 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Fisher of Las Vegas, NV is reported in the CMS Open Payments database as having received $13,060 across 681 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,029 54
2024 General $2,389 98
2023 General $2,270 120
2022 General $2,437 123
2021 General $2,612 102
2020 General $966 70
2019 General $1,357 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Fisher
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Christopher Fisher were reported at $1,029. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Christopher Fisher Pain Medicine median Middle half National median
2019 $1,357 $506 $144–$1,566 $163
2020 $966 $315 $96–$934 $114
2021 $2,612 $452 $134–$1,237 $132
2022 $2,437 $475 $124–$1,407 $149
2023 $2,270 $480 $136–$1,384 $160
2024 $2,389 $521 $164–$1,511 $164
2025 $1,029 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,169 120 payments
  2. Scilex Pharmaceuticals Inc. $1,757 119 payments
  3. Collegium Pharmaceutical, Inc. $1,739 115 payments
  4. Forte Bio-Pharma LLC $1,227 35 payments
  5. IBSA Pharma Inc. $951 53 payments
  6. RedHill Biopharma Inc. $885 4 payments
  7. Arbor Pharmaceuticals, Inc. $592 66 payments
  8. AbbVie, Inc. $361 21 payments
  9. Protega Pharmaceutials LLC $333 16 payments
  10. Xtant Medical Inc $332 3 payments
  11. Other $2,714 129 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,230 677 payments
  2. Consulting Fee $830 1 payment
  3. Gift $0 3 payments
Products named General payments · program years 2019–2025
  1. RELISTOR $2,019 112 payments
  2. ZTLido $1,445 97 payments
  3. PROLATE Pain $1,086 33 payments
  4. PROLATE Pain $1,086 33 payments
  5. PROLATE Pain $1,086 33 payments
  6. NALOCET $1,086 33 payments
  7. PROLATE Pain $897 25 payments
  8. Movantik $885 4 payments
  9. Tirosint $884 50 payments
  10. Licart $882 50 payments
  11. Other $7,989 470 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,486

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$130,894

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

28.5%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 16 $37,521
Belbuca Buprenorphine Hcl Brand 25 $21,650
Ztlido Lidocaine Brand 17 $16,070
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 104 $14,879
Linzess Linaclotide Brand 14 $7,676
Lidocaine Generic 29 $5,679
Movantik Naloxegol Oxalate Brand 12 $5,522
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 183 $4,766
Pregabalin Generic 46 $2,972
Oxycodone Hcl Generic 118 $2,893

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$87,865

Of which drugs: $156

Medicare patients

271

Average age 68

Services billed

1,304

171 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Depression 36%
Ischemic heart disease 28%
COPD 25%
Chronic kidney disease 21%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 27 128 $97
Injection, ketorolac tromethamine, per 15 mg J1885 Office 22 120 $58

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROLATE
$426 — —
ZTLido
$208 17 —
BELBUCA
$167 25 —
ROXYBOND
$166 — —
Tirosint
$130 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

681 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record